Jade Biosciences, Inc. SEC filings JBIO
Jade Biosciences, Inc. has 509 filings in SEC EDGAR's recent list, going back to Jan 8, 2020. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 10, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 30, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | May 15, 2026 | — |
| EFFECT | Filing | May 15, 2026 | — |
| CORRESP | Letter to the SEC | May 13, 2026 | — |
| CORRESP | Letter to the SEC | May 13, 2026 | — |
| UPLOAD | Letter from the SEC | May 13, 2026 | — |
| UPLOAD | Letter from the SEC | May 13, 2026 | — |
| POS EX | Filing | Mar 6, 2026 | — |
| POS EX | Filing | Mar 6, 2026 | — |
| EFFECT | Filing | Dec 30, 2025 | — |
| CORRESP | Letter to the SEC | Dec 23, 2025 | — |
| UPLOAD | Letter from the SEC | Dec 23, 2025 | — |
| EFFECT | Filing | Dec 19, 2025 | — |
| CORRESP | Letter to the SEC | Dec 17, 2025 | — |
| 8-A12B/A | Filing | Aug 13, 2025 | — |
| 425 | Filing | Apr 9, 2025 | — |
| 425 | Filing | Apr 9, 2025 | — |
| 425 | Filing | Apr 9, 2025 | — |
| 425 | Filing | Apr 7, 2025 | — |
| 425 | Filing | Apr 7, 2025 | — |
| 425 | Filing | Mar 26, 2025 | — |
| SEC STAFF LETTER | Filing | Mar 25, 2025 | — |
| EFFECT | Filing | Mar 25, 2025 | — |
| CORRESP | Letter to the SEC | Mar 24, 2025 | — |
| CORRESP | Letter to the SEC | Mar 24, 2025 | — |
| CORRESP | Letter to the SEC | Mar 24, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 21, 2025 | — |
| CORRESP | Letter to the SEC | Mar 14, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 11, 2025 | — |
| 425 | Filing | Mar 3, 2025 | — |
| CORRESP | Letter to the SEC | Feb 24, 2025 | — |
| SEC STAFF LETTER | Filing | Feb 18, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 18, 2025 | — |
| 425 | Filing | Feb 10, 2025 | — |
| 425 | Filing | Feb 4, 2025 | — |
| 425 | Filing | Jan 24, 2025 | — |
| 425 | Filing | Jan 13, 2025 | — |
| RW | Filing | Nov 25, 2024 | — |
| 425 | Filing | Nov 18, 2024 | — |
| 425 | Filing | Oct 31, 2024 | — |
| 425 | Filing | Oct 31, 2024 | — |
| 425 | Filing | Oct 31, 2024 | — |
| 425 | Filing | Oct 31, 2024 | — |
| 425 | Filing | Oct 31, 2024 | — |
| EFFECT | Filing | Aug 23, 2022 | — |
| CORRESP | Letter to the SEC | Aug 19, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 18, 2022 | — |
| EFFECT | Filing | Jun 29, 2021 | — |
| CERT | 8a cert | Jun 29, 2021 | — |
| 8-A12B | Form 8-a12b | Jun 25, 2021 | — |
| CORRESP | Letter to the SEC | Jun 25, 2021 | — |
| CORRESP | Letter to the SEC | Jun 25, 2021 | — |
| CORRESP | Letter to the SEC | Jun 24, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 21, 2021 | — |
| CORRESP | Letter to the SEC | Jun 9, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 2, 2021 | — |
| DRS | Filing | May 6, 2021 | — |
| D | Filing | Aug 14, 2020 | — |
| D | Filing | Jan 8, 2020 | — |
Showing 58 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- JBIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1798749
- Former names
- Aerovate Therapeutics, Inc. (until Apr 30, 2025)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.